Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BuCyMel Conditioning for Allogeneic HCT in Hematological Malignancies
NCT00176839Phase 3Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jun 2000
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of busulfan, cyclophosphamide and melphalan in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Masonic Cancer Center. Primary endpoint: Disease-free Survival at 1 year. Started Jun 2000; status: terminated.
02
Drugs
busulfancyclophosphamidemelphalan
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00176839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176839.